OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis $0.0089 0.00 (-35.51%) As of 07/1/2025 11:44 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Appili Therapeutics Stock (OTCMKTS:APLIF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Appili Therapeutics alerts:Sign Up Key Stats Today's Range$0.0089▼$0.008950-Day Range$0.01▼$0.0252-Week Range$0.01▼$0.03Volume10,000 shsAverage Volume22,560 shsMarket Capitalization$1.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Read More Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLIF Stock News HeadlinesAppili Therapeutics Inc.: Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational ResultsJune 26, 2025 | finanznachrichten.deAppili Therapeutics Inc. (APLI.TO) - Yahoo FinanceJune 26, 2025 | ca.finance.yahoo.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 2 at 2:00 AM | Brownstone Research (Ad)Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational ResultsJune 25, 2025 | financialpost.comFAppili Therapeutics Reports Fiscal Year 2025 Financial and Operational ResultsJune 25, 2025 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.May 30, 2025 | finanznachrichten.deAppili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.May 30, 2025 | globenewswire.comSaptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of MetronidazoleMay 20, 2025 | finance.yahoo.comSee More Headlines APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed this year? Appili Therapeutics' stock was trading at $0.0280 at the start of the year. Since then, APLIF stock has decreased by 68.2% and is now trading at $0.0089. View the best growth stocks for 2025 here. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2024Today7/02/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:APLIF CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.89 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-134.60% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$70 thousand Price / Sales15.42 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares121,270,000Free Float106,908,000Market Cap$1.08 million OptionableNot Optionable Beta-0.59 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:APLIF) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.